ArticleESMO open2024
A phase I dose-escalation study of LRP5/6 antagonist BI 905677 in patients with advanced solid tumors.
H-J Lenz et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
7 papers cite it
this papercites it
ArticleESMO open2024
H-J Lenz et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.